SynPhNe Secures $5 Million in Series A Funding to Transform Neurorehabilitation and Beyond

SynPhNe™, a pioneer in stroke and traumatic brain injury (TBI) rehabilitation, has successfully raised $5 million in funding to propel its innovative solutions further into the healthcare market. Specializing in wearable technologies that synchronize cognitive and motor function training, SynPhNe's cutting-edge platform utilizes real-time EEG and EMG data to create a self-correcting learning loop. This approach provides deep insights into patient-specific deficits, allowing for customized rehabilitation that enhances recovery outcomes. Currently partnered with several prestigious hospitals across the United States, SynPhNe's platform is commercially available and is supported by its FDA Class II 510(k) exempt status. The new funding will be strategically invested in expanding its presence in the North American market, improving product features, and enhancing user engagement through additional research and development. While the company's primary focus is on neurorehabilitation, the funding will also support its initial foray into sports peak performance in Asia, where it is already seeing promising results. Moreover, SynPhNe's commitment to innovation is evident as it explores applications within the Learning Disability domain, aiming to help diverse populations achieve their full potential. With this funding round, SynPhNe not only aims to enhance therapeutic options for patients with cognitive and motor difficulties but also strives to redefine the standards of care in rehabilitation, ensuring that technology plays a transformative role in recovery and performance enhancement across various fields.